AG
CRSP icon

Advisor Group’s CRISPR Therapeutics CRSP Stock Holding History

Advisor Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$768K Buy
12,608
+8,780
+229% +$479K 0.01% 1372
2019
Q3 		$157K Buy
3,828
+973
+34% +$46.5K ﹤0.01% 2515
2019
Q2 		$134K Sell
2,855
-2,671
-48% -$107K ﹤0.01% 2634
2019
Q1 		$197K Buy
5,526
+950
+21% +$32.8K ﹤0.01% 2296
2018
Q4 		$131K Sell
4,576
-5,054
-52% -$176K ﹤0.01% 2413
2018
Q3 		$427K Buy
9,630
+1,609
+20% +$84.3K ﹤0.01% 1576
2018
Q2 		$471K Buy
8,021
+6,827
+572% +$389K 0.01% 1348
2018
Q1 		$55K Buy
1,194
+94
+9% +$3.88K ﹤0.01% 2983
2017
Q4 		$26K Buy
1,100
+200
+22% +$3.8K ﹤0.01% 3534
2017
Q3 		$16K Hold
900
– – ﹤0.01% 3684
2017
Q2 		$14K Buy
900
+600
+200% +$9.91K ﹤0.01% 3723
2017
Q1 		$7K Buy
+300
New +$5.89K ﹤0.01% 3958

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Advisor Group's CRSP Position: Q4 2019 in Review

Advisor Group increased its CRISPR Therapeutics (CRSP) stake by 229% in Q4 2019, buying an estimated $479K and bringing the position to 12,608 shares worth $768K. The position accounts for 0.01% of the portfolio, ranked #1372.

Advisor Group first reported a position in CRSP in Q1 2017 and has held it in 12 quarters since. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • Advisor Group held 12,608 shares of CRISPR Therapeutics worth $768K as of Q4 2019.
  • Advisor Group bought 8,780 CRISPR Therapeutics shares in Q4 2019, an estimated $479K.
  • CRISPR Therapeutics made up 0.01% of Advisor Group's portfolio in Q4 2019, its #1372 holding.
  • Advisor Group first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 12 quarters since.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.